Psychiatr. praxi. 2023;24(2):70-75 | DOI: 10.36290/psy.2023.015

Serious states induced by taking psychopharmacs and their treatment

prof. MUDr. Eva Češková, CSc.1, 2, 3, PharmDr. Bc. Kateřina Horská, Ph.D.4, 5
1 Psychiatrická klinika LF MU a FN Brno
2 KPN LF Ostravská univerzita
3 Oddělení psychiatrie, FN Ostrava
4 Úsek klinické farmacie, Nemocniční lékárna, Fakultní nemocnice Brno
5 Ústav farmakologie a toxikologie, Farmaceutická fakulta, Masarykova univerzita, Brno

The article summarizes current knowledge of severe states associated with taking antidepressants and antipsychotics. These states usually require immediate intervention and include acute and tardive dystonia, tardive dyskinesias, neuroleptic malignant syndrome, serotonin syndrome and withdrawal-induced syndrome. Regarding their severity, and sometimes unexpectedly manifestation, they represent severe adverse events subjected to compulsory reporting to State Institute for Drug Control, Department of Pharmacovigilance.

Keywords: acute dystonia, tardive dystonia, tardive dyskinesias, neuroleptic malignant syndrome, serotonin syndrome, withdrawal­induced syndrome, pharmacovigilance.

Accepted: May 31, 2023; Published: June 13, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Češková E, Horská K. Serious states induced by taking psychopharmacs and their treatment. Psychiatr. praxi. 2023;24(2):70-75. doi: 10.36290/psy.2023.015.
Download citation

References

  1. Ustohal L, Baláž M. Léčba EPS­‑akutní a tardivní dystonie a dyskineze, 2018. Available from: https://postupy­‑pece.psychiatrie.cz/obecnapsychiatrie/lecba.
  2. Loonen AJ, Ivanova SA. Neurobiological mechanisms associated with antipsychotic drug­‑induced dystonia J Psychopharmacol. 2021;35:3-14. Go to original source... Go to PubMed...
  3. Hasan A, Wobrock T, Gaebel W, et al. Germany Society of Psychotherapy and Psychosomatics (DGPPN); German Association of Psychiatry. Nationale und internationale Leitlinien zur Schizophrenie. Update 2013 zum Stand der Empfehlungen zur antipsychotischen Medikation. Nervenarzt. 2013;84:1359-60, 1362-4, 1366-8. Go to original source...
  4. Vasan S, Padhy RK. Tardive Dyskinesia. 2022. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. 2022. PMID: 28846278American Psychiatric Association, 1994. Diagnostic and statistical manual of mental disorders (DSM-4VR), Washington (DC).
  5. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-5VR), Washington (DC) 2013. Go to original source...
  6. Citrome L, Isaacson SH, Larson D, Kremens D. Tardive dyskinesia in older persons taking antipsychotics. Neuropsychiatr Dis Treat. 2021;17:3127-3134. Go to original source...
  7. Stahl SM, SY S, Maguire GA. How and when to treat the most common adverse effects of antipsychotics: expert review from research to clinical practice. Acta Psychiatr Scand. 2021;143:172-180. Go to original source... Go to PubMed...
  8. Halff EF, Rutigliano G, Garcia­‑Hidalgo A, et al. Trace amine­‑associated receptor 1 (TAAR1) agonism as a new treatment strategy for schizophrenia and related disorders. Trends Neurosci. 2023;46(1):60-74. Go to original source...
  9. Baumgärtner J, Grohmann R, Bleich S, et al. Atypical dyskinesias under treatment with antipsychotic drugs: Report from the AMSP multicenter drug safety project. World J Biol Psychiatry. 2022;23:151-164. Go to original source...
  10. Tse L. Neuroleptic malignant syndrome: a review from a clinically oriented perspective. Curr Neuropharmacol. 2015; 13:395-406. Go to original source... Go to PubMed...
  11. Češková E, Horská K. Neuroleptický maligní syndrom a jeho řešení v klinické praxi z perspektivy současných doporučených postupů. Čes a slov Psychiatrie. 2021;117:42-47.
  12. Guinart D, Misawa F, Rubio JM, et al. systematic review and pooled, patient­‑level analysis of predictors of mortality in neuroleptic malignant syndrome. Acta Psychiatr Scand. 2021;144(4):329-341. Go to original source... Go to PubMed...
  13. Alfshawy M, Bitar Z, Elgazzar A, Elzoueiry M. Neuroleptic malignant syndrome following COVID-19 vaccination. Am J Emerg Med. 2021;S0735-6757:00117. Go to original source...
  14. Nagamine T. Neuroleptic malignant syndrome associated with COVID-19 vaccination. CJEM 2022;24:349-350. Go to original source... Go to PubMed...
  15. Odagaki Y. Atypical neuroleptic malignant syndrome or serotonin toxicity associated with atypical antipsychotics? Curr Drug Saf. 2009;4:84-93. Go to original source...
  16. Reeves RR, Ladner ME, Smith P. About serotonin syndrome. J Miss State Med Assoc. 2013;54:286-8. Go to PubMed...
  17. Scotton WJ, Hill LJ, Williams AC, Barnes NM. Serotonin syndrome: Pathophysiology, clinical features, management, and potential future directions. Int J Tryptophan Res. 2019; 12:1178646919873925 Go to original source...
  18. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352:1112-1120. Go to original source...
  19. Chouinard G, Chouinard VA. New classification of selective serotonin reuptake inhibitor withdrawal. Psychother Psychosom. 2015;84(2):63-71. Go to original source...
  20. Cosci F, Chouinard G. Acute and persistent withdrawal syndromes following discontinuation of psychotropic medications. Psychother Psychosom. 2020;89(5):283-306. Go to original source...
  21. Davies J, Read J. A systematic review into the incidence, severity, and duration of antidepressant withdrawal effects: are guidelines evidence­‑based? Addict Behav. 2019;97:111-121. Go to original source... Go to PubMed...
  22. Fornaro M, Cattaneo CI, De Berardis D, et al. Antidepressant discontinuation syndrome: A state­‑of­‑the­‑art clinical review. Eur Neuropsychopharmacol. 2023;66:1-10.Další literatura u autora a na www.psychiatriepropraxi.cz Go to original source... Go to PubMed...
  23. Cerovecki A, Musil R, Klimke A, et al. Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations. CNS Drugs 2013; 27(7):545-72. Go to original source...
  24. Chouinard G, Samaha AN, Chouinard VA, et al. Antipsychotic­‑induced dopamine supersensitivity psychosis: Pharmacology, criteria, and therapy. Psychother Psychosom. 2017;86:189-219. Go to original source...
  25. de Leon J, Ruan CJ, Schoretsanitis G, De Las Cuevas C. A Rational use of clozapine based on adverse drug reactions, pharmacokinetics, and clinical pharmacopsychology. Psychother Psychosom. 2020;89:200-214. Go to original source...
  26. Blackman G, Oloyede E. Clozapine discontinuation withdrawal symptoms in schizophrenia. Ther Adv Psychopharmacol. 2021;11:20451253211032053. Go to original source...
  27. Lander M, Bastiampillai T, Sareen J. Review of withdrawal catatonia: what does this reveal about clozapine? Transl Psychiatry 2018;8:139. Go to original source...
  28. Belteczki Z, Julia Ujvari J, Dome P. Clozapine withdrawal­‑induced malignant catatonia or neuroleptic malignant syndrome: A case report and a brief review of the literature. Clin Neuropharmacol. 2021;44:148-153. Go to original source... Go to PubMed...




Psychiatry for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.